Literature DB >> 18268090

Malaria treatment with atovaquone-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria.

Mark E Polhemus1, Shon Remich, Bernhards Ogutu, John Waitumbi, Marc Lievens, W Ripley Ballou, D Gray Heppner.   

Abstract

Eighty adults in areas of Kenya where malaria is holoendemic received presumptive treatment with atovaquone-proguanil and were followed closely. The time to the first Plasmodium falciparum parasitemia was 32 days. This prolonged prophylaxis period has implications for study design when used in malaria intervention trials and cautiously suggests clinical investigation of potential preexposure prophylaxis of malaria.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18268090      PMCID： PMC2292568          DOI： 10.1128/AAC.01367-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Time to reappearance of malaria parasites following various drug treatment regimens in a holoendemic area of western Kenya.

Authors:  G D Shanks; B O Ragama; A J Oloo
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 May-Jun       Impact factor: 2.184

2.  Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration.

Authors:  M D Edstein; B M Kotecka; K L Anderson; D J Pombo; D E Kyle; K H Rieckmann; M F Good
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand.

Authors:  S Looareesuwan; C Viravan; H K Webster; D E Kyle; D B Hutchinson; C J Canfield
Journal:  Am J Trop Med Hyg       Date:  1996-01       Impact factor: 2.345

4.  Drug-free holidays: pre-travel versus during travel malaria chemoprophylaxis.

Authors:  G Dennis Shanks; Alan J Magill; David O Freedman; Jay S Keystone; David J Bradley; Robert Steffen
Journal:  Am J Trop Med Hyg       Date:  2007-07       Impact factor: 2.345

5.  Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission I. Description of study site, general methodology, and study population.

Authors:  P B Bloland; T K Ruebush; J B McCormick; J Ayisi; D A Boriga; A J Oloo; R Beach; W Hawley; A Lal; B Nahlen; V Udhayakumar; C C Campbell
Journal:  Am J Trop Med Hyg       Date:  1999-04       Impact factor: 2.345

6.  Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II).

Authors:  Andrea K Boggild; Monica E Parise; Linda S Lewis; Kevin C Kain
Journal:  Am J Trop Med Hyg       Date:  2007-02       Impact factor: 2.345

7.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.

Authors:  Pedro L Alonso; Jahit Sacarlal; John J Aponte; Amanda Leach; Eusebio Macete; Jessica Milman; Inacio Mandomando; Bart Spiessens; Caterina Guinovart; Mateu Espasa; Quique Bassat; Pedro Aide; Opokua Ofori-Anyinam; Margarita M Navia; Sabine Corachan; Marc Ceuppens; Marie-Claude Dubois; Marie-Ange Demoitié; Filip Dubovsky; Clara Menéndez; Nadia Tornieporth; W Ripley Ballou; Ricardo Thompson; Joe Cohen
Journal:  Lancet       Date:  2004 Oct 16-22       Impact factor: 79.321

8.  Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro.

Authors:  Geoff A Butcher; Robert E Sinden
Journal:  Am J Trop Med Hyg       Date:  2003-01       Impact factor: 2.345

9.  A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.

Authors:  Philip Bejon; Jedidah Mwacharo; Oscar Kai; Tabitha Mwangi; Paul Milligan; Stephen Todryk; Sheila Keating; Trudie Lang; Brett Lowe; Caroline Gikonyo; Catherine Molyneux; Greg Fegan; Sarah C Gilbert; Norbert Peshu; Kevin Marsh; Adrian V S Hill
Journal:  PLoS Clin Trials       Date:  2006-10-20

10.  A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.

Authors:  Vasee S Moorthy; Egeruan B Imoukhuede; Paul Milligan; Kalifa Bojang; Sheila Keating; Pauline Kaye; Margaret Pinder; Sarah C Gilbert; Gijs Walraven; Brian M Greenwood; Adrian S V Hill
Journal:  PLoS Med       Date:  2004-10-26       Impact factor: 11.069
View more
  2 in total

1.  Unanticipated CNS Safety Signal in a Placebo-Controlled, Randomized Trial of Co-Administered Atovaquone-Proguanil and Amodiaquine.

Authors:  Stephan Chalon; M Farouk Chughlay; Nada Abla; Andre Marie Tchouatieu; Amina Haouala; Ben Hutter; Ulrike Lorch; Fiona Macintyre
Journal:  Clin Pharmacol Ther       Date:  2021-09-14       Impact factor: 6.903

2.  Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.

Authors:  C Preston Neff; Thomas Ndolo; Apurva Tandon; Yuichiro Habu; Ramesh Akkina
Journal:  PLoS One       Date:  2010-12-21       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.